RENVISTOBART
UNII 81J55YFQ16

Substance Identification & Data

This profile provides standardized clinical and technical data for Renvistobart, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 81J55YFQ16.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2725062-35-9 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

81J55YFQ16

CAS Registry Number

2725062-35-9

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

RENVISTOBART

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C131907

National Cancer Institute reference terminology for clinical and research data.

INN ID

12465

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Renvistobart

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Renvistobart. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Renvistobart

Common Names & Synonyms

ANTI-TIGIT MONOCLONAL ANTIBODY BMS-986207

Immunoglobulin G1 [247-alanine,248-glutamic acid,250-alanine,343-serine,344-serine,de-C-terminal-lysine], anti-(human T cell immunoreceptor with Ig and ITIM domains) (human monoclonal BMS-986207 γ1-chain), disulfide with human monoclonal BMS-986207 κ-chain, dimer

Immunoglobulin G1-kappa, anti-[Homo sapiens TIGIT (T cell immunoreceptor with Ig domain and ITIM, V-set Ig member 9, VSIG9, V-set and transmembrane member 3, VSTM3)], Homo sapiens monoclonal antibody (gamma1 heavy chain Homo sapiens (1-459) [VH (Homo sapiens IGHV4-61*01 (98.0%) -(IGHD) -IGHJ3*01 (92.3%), CDR-IMGT [10.7.22] (26-35.53-59.98-119)) (1-130) -Homo sapiens IGHG1*03, G1m3, nG1m1 CH1 R120, CH3 E12, M14, G1v43 CH2 A1.3, E1.2, A1, G1v60 S115, S116 (CH1 R120 (227) (131-228), hinge 1-15 (229-243), CH2 L1.3>A (247), L1.2>E (248), G1>A (250), A115>S (343), P116>S (344) (244-353), CH3 E12 (369), M14 (371) (354-458), CHS K2>del (459))(131-459)], (233-216')-disulfide with kappa light chain Homo sapiens (1'-216') [V- APPA (Homo sapiens IGKV3-11*01 (100%) -IGKJ3*01 (100%), CDR-IMGT [6.3.11](27-32.50-52.89-99)) (1'-109') -Homo sapiens IGKC*01(100%), Km3 A45.1 (155), V101 (193) (110'-216')]; dimer (239-239'':242-242'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1 lacking the glutamine synthetase (GS-KO) gene, glycoform alfa)

Renvistobart [WHO-DD]

renvistobart [INN]